JPWO2019191633A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019191633A5 JPWO2019191633A5 JP2020551860A JP2020551860A JPWO2019191633A5 JP WO2019191633 A5 JPWO2019191633 A5 JP WO2019191633A5 JP 2020551860 A JP2020551860 A JP 2020551860A JP 2020551860 A JP2020551860 A JP 2020551860A JP WO2019191633 A5 JPWO2019191633 A5 JP WO2019191633A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- lysate
- component
- pseudomonas aeruginosa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 72
- 239000006166 lysate Substances 0.000 claims 30
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 25
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 22
- 101710004799 sm-amp-x Proteins 0.000 claims 22
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 claims 19
- 230000035772 mutation Effects 0.000 claims 18
- 229920000023 polynucleotide Polymers 0.000 claims 18
- 239000002157 polynucleotide Substances 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 15
- 230000002101 lytic Effects 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 230000000694 effects Effects 0.000 claims 10
- 241000894006 Bacteria Species 0.000 claims 9
- 230000001580 bacterial Effects 0.000 claims 9
- 230000000087 stabilizing Effects 0.000 claims 7
- 206010060945 Bacterial infection Diseases 0.000 claims 6
- 210000002966 Serum Anatomy 0.000 claims 6
- 230000003115 biocidal Effects 0.000 claims 6
- 101700056644 BDP1 Proteins 0.000 claims 5
- 101710021364 CHORDC1 Proteins 0.000 claims 5
- 101700079369 CHP1 Proteins 0.000 claims 5
- 101700056065 CHP2 Proteins 0.000 claims 5
- 241001510512 Chlamydia phage 2 Species 0.000 claims 5
- 241000839426 Chlamydia virus Chp1 Species 0.000 claims 5
- VNUQOJUAIRBYQO-PPAUOFQQSA-N Esculentin Chemical group O([C@H]1[C@@H](OC)C[C@@H](O[C@@H]1C)O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2CC3=CC[C@@]4(O)[C@@]5(O)CC[C@](O)([C@@]5(C)[C@H](O)[C@@H](O)C4[C@@]3(C)CC2)C(C)=O)C[C@H]1OC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](OC)[C@H]1O VNUQOJUAIRBYQO-PPAUOFQQSA-N 0.000 claims 5
- 101710010813 SERPINA3K Proteins 0.000 claims 5
- 101700063220 SPI1 Proteins 0.000 claims 5
- 101710010817 Serpina3n Proteins 0.000 claims 5
- 101710015462 TESC Proteins 0.000 claims 5
- 239000003242 anti bacterial agent Substances 0.000 claims 5
- 125000002091 cationic group Chemical group 0.000 claims 5
- 101710009906 lbp-2 Proteins 0.000 claims 5
- 108010053632 lipopolysaccharide-binding protein Proteins 0.000 claims 5
- 241000894007 species Species 0.000 claims 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- 125000003345 AMP group Chemical group 0.000 claims 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 2
- 241000588923 Citrobacter Species 0.000 claims 2
- 241000588914 Enterobacter Species 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 2
- 241000588748 Klebsiella Species 0.000 claims 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 2
- 229940118695 Yersinia pestis Drugs 0.000 claims 2
- 241000607479 Yersinia pestis Species 0.000 claims 2
- 229940079866 intestinal antibiotics Drugs 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000006011 modification reaction Methods 0.000 claims 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-O (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-O 0.000 claims 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N Amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N Cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N Cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims 1
- 229960004682 Cefoperazone Drugs 0.000 claims 1
- 229960000484 Ceftazidime Drugs 0.000 claims 1
- 229920002676 Complementary DNA Polymers 0.000 claims 1
- AVAACINZEOAHHE-VFZPANTDSA-N Doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229960002182 IMIPENEM Drugs 0.000 claims 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N IMIPENEM Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N Meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims 1
- 229940049954 Penicillin Drugs 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N Piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N Ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims 1
- 229960004659 Ticarcillin Drugs 0.000 claims 1
- 229960000707 Tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 229960004821 amikacin Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- -1 aminoglycoside Chemical compound 0.000 claims 1
- 229960000626 benzylpenicillin Drugs 0.000 claims 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims 1
- 229960002100 cefepime Drugs 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 229960000895 doripenem Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960003376 levofloxacin Drugs 0.000 claims 1
- 229960002260 meropenem Drugs 0.000 claims 1
- 230000001717 pathogenic Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 229960002292 piperacillin Drugs 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650235P | 2018-03-29 | 2018-03-29 | |
| US62/650,235 | 2018-03-29 | ||
| US201862721969P | 2018-08-23 | 2018-08-23 | |
| US62/721,969 | 2018-08-23 | ||
| US201862722793P | 2018-08-24 | 2018-08-24 | |
| US62/722,793 | 2018-08-24 | ||
| PCT/US2019/024912 WO2019191633A2 (en) | 2018-03-29 | 2019-03-29 | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519083A JP2021519083A (ja) | 2021-08-10 |
| JPWO2019191633A5 true JPWO2019191633A5 (es) | 2022-04-04 |
Family
ID=68060804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551860A Pending JP2021519083A (ja) | 2018-03-29 | 2019-03-29 | 溶解素−抗微生物ペプチド（ａｍｐ）ポリペプチドコンストラクト、溶解素、それをコードする単離ポリヌクレオチド及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11773140B2 (es) |
| EP (1) | EP3775192A4 (es) |
| JP (1) | JP2021519083A (es) |
| KR (1) | KR20200136980A (es) |
| CN (1) | CN112368376A (es) |
| AU (1) | AU2019245369A1 (es) |
| BR (1) | BR112020019484A2 (es) |
| CA (1) | CA3095484A1 (es) |
| IL (1) | IL277119A (es) |
| MX (1) | MX2020010075A (es) |
| WO (1) | WO2019191633A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015200783A2 (en) * | 2014-06-26 | 2015-12-30 | The Rockefeller University | Acinetobacter lysins |
| US20210330738A1 (en) * | 2018-03-29 | 2021-10-28 | Contrafect Corporation | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria |
| CA3095484A1 (en) | 2018-03-29 | 2019-10-03 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| US10988520B2 (en) * | 2018-03-29 | 2021-04-27 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| JP2022526978A (ja) * | 2019-04-05 | 2022-05-27 | コントラフェクト コーポレイション | ヒト血清の存在下でシュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体 |
| KR20220029746A (ko) * | 2019-07-05 | 2022-03-08 | 콘트라펙트 코포레이션 | 항미생물성 박테리오파지 유도된 폴리펩타이드 및 이의 그람 음성 및 항산성 세균에 대한 사용 |
| EP4058468A4 (en) * | 2019-11-14 | 2024-04-10 | Contrafect Corporation | POLYPEPTIDE CONSTRUCTIONS OF ANTIMICROBIAL PEPTIDE LYSINE (AMP), LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEREFOR AND USES THEREOF |
| WO2021211303A1 (en) * | 2020-04-14 | 2021-10-21 | Contrafect Corporation | Antiviral, bacteriophage-derived polypeptides and their use against viruses |
| US20210324359A1 (en) * | 2020-04-17 | 2021-10-21 | Contrafect Corporation | Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis |
| IL307148A (en) * | 2021-03-26 | 2023-11-01 | Contrafect Corp | Amorinin, lysins and antimicrobial lysine-peptide structures are active against gram-negative bacteria |
| WO2022236088A1 (en) * | 2021-05-06 | 2022-11-10 | Bioharmony Therapeutics Inc. | Lysin polypeptide compositions and methods of use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006050737A1 (en) | 2004-11-12 | 2006-05-18 | Novozymes A/S | Polypeptides having antimicrobial activity and polynucleotides encoding same |
| CA2765657A1 (en) | 2009-06-16 | 2010-12-23 | Tokai University | Anti-gram-negative bacteria agent |
| EP3363896A1 (en) * | 2009-06-26 | 2018-08-22 | Lysando AG | Antimicrobial agents |
| KR101711062B1 (ko) * | 2009-06-26 | 2017-02-28 | 카톨리에케 유니버시테이트 루벤 | 항균제 |
| US8846865B2 (en) | 2009-08-24 | 2014-09-30 | Lysando Ag | Endolysin OBPgpLYS |
| EP2468856A1 (en) | 2010-12-23 | 2012-06-27 | Lysando Aktiengesellschaft | Antimicrobial Agents |
| WO2012145573A2 (en) | 2011-04-21 | 2012-10-26 | Universiteit Utrecht Holding Bv | Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock |
| EP2993181A1 (en) * | 2011-04-27 | 2016-03-09 | Lysando AG | New antimicrobial agents |
| US9518252B2 (en) | 2011-05-26 | 2016-12-13 | Dsm Ip Assets B.V. | Listeria bacteriophage P825 and uses thereof |
| US8790639B2 (en) | 2012-03-28 | 2014-07-29 | The United States Of America, As Represented By The Secretary Of Agriculture | Enhanced antimicrobial lytic activity of a chimeric Ply187 endolysin |
| KR101391332B1 (ko) * | 2012-05-18 | 2014-05-07 | 연세대학교 산학협력단 | 카바페넴 제제에 내성을 보이는 아시네토박터 속의 균을 용균하는 박테리오파아지 |
| US9388400B2 (en) * | 2012-06-29 | 2016-07-12 | Lysando Ag | Composition for use in mycobacteria diagnosis |
| CN102861324A (zh) * | 2012-10-17 | 2013-01-09 | 重庆市第三人民医院 | 治疗耐碳青霉烯类鲍曼不动杆菌感染的生物试剂 |
| WO2015200783A2 (en) | 2014-06-26 | 2015-12-30 | The Rockefeller University | Acinetobacter lysins |
| US11357833B2 (en) | 2015-09-17 | 2022-06-14 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
| KR102000120B1 (ko) | 2017-01-26 | 2019-07-15 | 주식회사 코미팜 | 이유 자돈의 대장균증을 예방하기 위한 재조합 p22 라이소자임 - pmap36 융합 단백질을 이용한 장내독소형 대장균(etec) 고스트 백신 조성물 |
| BR112020011433A2 (pt) | 2017-12-12 | 2020-12-01 | Contrafect Corporation | identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa |
| US10988520B2 (en) | 2018-03-29 | 2021-04-27 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| CA3095484A1 (en) | 2018-03-29 | 2019-10-03 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| US20210330738A1 (en) | 2018-03-29 | 2021-10-28 | Contrafect Corporation | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria |
| IL313959A (en) * | 2018-08-23 | 2024-08-01 | Contrafect Corp | Lysine Polypeptide Templates - Antimicrobial Peptide, Lysines, Isolated Polynucleotides Encoding Them and Their Uses |
| US20210324359A1 (en) * | 2020-04-17 | 2021-10-21 | Contrafect Corporation | Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis |
-
2019
- 2019-03-29 CA CA3095484A patent/CA3095484A1/en active Pending
- 2019-03-29 JP JP2020551860A patent/JP2021519083A/ja active Pending
- 2019-03-29 WO PCT/US2019/024912 patent/WO2019191633A2/en active Application Filing
- 2019-03-29 BR BR112020019484-0A patent/BR112020019484A2/pt unknown
- 2019-03-29 CN CN201980036007.XA patent/CN112368376A/zh active Pending
- 2019-03-29 AU AU2019245369A patent/AU2019245369A1/en active Pending
- 2019-03-29 KR KR1020207031049A patent/KR20200136980A/ko not_active Application Discontinuation
- 2019-03-29 EP EP19776817.9A patent/EP3775192A4/en active Pending
- 2019-03-29 MX MX2020010075A patent/MX2020010075A/es unknown
- 2019-03-29 US US17/041,691 patent/US11773140B2/en active Active
-
2020
- 2020-09-03 IL IL277119A patent/IL277119A/en unknown
-
2023
- 2023-08-18 US US18/452,038 patent/US20240018192A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506769A5 (es) | ||
| JP2024010053A5 (es) | ||
| Zhu et al. | Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections | |
| AU2016324307B2 (en) | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby | |
| ES2579806T3 (es) | Agentes antimicrobianos | |
| US11690899B2 (en) | Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection | |
| Wang et al. | The antibacterial activity of E. coli bacteriophage lysin lysep3 is enhanced by fusing the Bacillus amyloliquefaciens bacteriophage endolysin binding domain D8 to the C-terminal region | |
| JPWO2019191633A5 (es) | ||
| JP2024010053A (ja) | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 | |
| Li et al. | Synergism between host defence peptides and antibiotics against bacterial infections | |
| JP7288851B2 (ja) | エンテロコッカス属細菌に対する新規抗微生物剤 | |
| JP2021525072A (ja) | 新規抗微生物タンパク質 | |
| RU2020128276A (ru) | МОДИФИЦИРОВАННЫЕ ЛИЗИНЫ PlySs2 И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ | |
| JP2021525092A (ja) | 新規抗微生物融合タンパク質 | |
| JPWO2019191598A5 (es) | ||
| JPWO2020046747A5 (es) | ||
| RU2020129467A (ru) | Полипептидные конструкции лизин-противомикробный пептид (amp), лизины, выделенные полинуклеотиды, кодирующие их, а также варианты их применения | |
| RU2020131450A (ru) | Происходящие из бактериофагов противомикробные полипептиды и их применение против грамотрицательных бактерий | |
| JPWO2020206327A5 (es) | ||
| CA3136126A1 (en) | Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum | |
| JPWO2021097192A5 (es) | ||
| US20220289867A1 (en) | Recombinant antimicrobial multidomain polypeptide, methods of producing and uses thereof | |
| JPWO2021180892A5 (es) | ||
| RU2021128336A (ru) | Лизины и их производные с бактерицидной активностью против pseudomonas aeruginosa в присутствии сыворотки крови человека | |
| RU2020129478A (ru) | Полипептидные конструкции лизин-противомикробный пептид (amp), лизины, выделенные полинуклеотиды, кодирующие их, а также варианты их применения |